AstraZeneca: 2020 adjusted EPS up 18%
(CercleFinance.com) - AstraZeneca has announced adjusted EPS of 4.
02 dollars for 2020, just above the consensus and up 18% at constant exchange rates compared with the previous year.
FY sales reached 26.6 billion dollars, up 10% at constant exchange rates relative to 2019, driven by higher sales (+11% at constant exchange rates), while collaboration revenue fell by 11% at constant exchange rates.
The trend was broadly unchanged in the fourth quarter, with sales up 10% at constant exchange rates to 7.4 billion dollars.
For 2021, the pharmaceuticals group expects double-digit sales growth (probably 13% to 15%) and adjusted EPS of 4.75 to 5 dollars.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
02 dollars for 2020, just above the consensus and up 18% at constant exchange rates compared with the previous year.
FY sales reached 26.6 billion dollars, up 10% at constant exchange rates relative to 2019, driven by higher sales (+11% at constant exchange rates), while collaboration revenue fell by 11% at constant exchange rates.
The trend was broadly unchanged in the fourth quarter, with sales up 10% at constant exchange rates to 7.4 billion dollars.
For 2021, the pharmaceuticals group expects double-digit sales growth (probably 13% to 15%) and adjusted EPS of 4.75 to 5 dollars.
Copyright (c) 2021 CercleFinance.com. All rights reserved.